New startup ideas · Health and bio · Healthcare and bio
startup idea
Allelium
The shared evidence network that makes every genetic test report smarter.
A subscription workbench for hospital and reference sequencing labs that drafts variant interpretations for cancer and rare disease reports.
- Software subscription
- Enterprise
- $10-100B market
- Network effects, winner takes most
- Global from day one
3/5
venture judge
2
similar startups, last 2 years (15 all-time)
96%
of 3 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Test it before you build it
$700 · 4 weeks · 20 prospects
For $700 in 4 weeks, prove that mid-size lab directors will sign a written reciprocity commitment to contribute variant classifications and pay $1,000 to reserve a founding pilot.
Riskiest assumption · Directors of mid-size sequencing labs will sign a written commitment to contribute their anonymized classifications and case-level evidence to a shared network - not merely consume it - and will pay before the network has scale.
1Focus group: who and where
Laboratory director or lead ABMGG-certified clinical molecular geneticist at a mid-size hospital or independent lab signing out 50-500 NGS oncology and rare-disease reports a month, with a variant-of-uncertain-significance backlog adding days to turnaround this quarter.
where to find 20 · The public ClinVar submitter directory (lab names and contacts for every lab that already shares classifications), ClinGen Variant Curation Expert Panel rosters, and the Association for Molecular Pathology (AMP) member network and its year-round webinars ahead of the November annual meeting.
2Sell first, build later
A 3-month founding-lab pilot for the first 10 labs: draft interpretations with full evidence dossiers on every hard variant within 48 hours, network lookup of what member labs concluded, starting within 30 days of the deposit - contingent on the lab's signed reciprocity commitment.
the ask · $500 per geneticist seat per month plus $10 per signed-out report; the founding pilot is $3,000 for 3 months, reserved with a $1,000 deposit
a real yes · A real yes is a paid $1,000 deposit plus a signed reciprocity LOI with a pilot start date; ClinVar-style goodwill, 'our geneticists loved the drafts', and unpaid evaluations are noes.
3Small experiments
The first one attacks the riskiest assumption; each ends with a number that says whether to run the next.
1. Reciprocity LOI sign test
$300 · 14 days
Pull 30 mid-size oncology and rare-disease labs from the ClinVar submitter directory and ClinGen rosters, book 12 twenty-minute calls with their directors, and ask each to sign a one-page reciprocity LOI: contribute anonymized classifications plus case-level evidence, receive full network access at founding pricing. A signature tests whether case-level evidence - not just the ClinVar-public classification - is actually shareable.
keep going if · 5 of 12 directors sign the reciprocity LOI within one week of the call
2. 48-hour VUS draft benchmark
$200 · 14 days
Ask 6 labs from the calls to send 10 anonymized hard VUS each under research-use-only terms. Founders return an evidence dossier and draft classification per variant within 48 hours, built by hand from ClinVar, gnomAD, literature, and functional databases. The lab's own geneticist scores each draft against what they signed out.
keep going if · 4 of 6 directors rate at least 7 of 10 drafts sign-out-ready after their own review and ask for more
3. Founding pilot deposit
$200 · 14 days
Pitch the 10 warmest labs a 3-month founding pilot at $3,000 - workbench drafts for every case plus network lookup - reserved by a $1,000 deposit invoiced up front. Founders run each pitch with that lab's own scored benchmark drafts on screen.
keep going if · 3 of 10 pitched labs pay the $1,000 deposit within 14 days
4Collect a deposit up front
Tesla took $1,000 refundable reservations for the Model 3 and $100 for the Cybertruck before building either: the deposit is the measurement, not the revenue.
$1,000
per prospect, refundable
how · A $1,000 deposit invoiced up front and credited to the $3,000 pilot - mid-size independent labs can pay an invoice without a procurement cycle, and pairing the money with the signed reciprocity LOI tests contribution and payment in one motion. The lab director signs both pages. set up: Stripe Invoicing ↗
what it reserves · One of 10 founding-lab pilot slots, the $500 per seat rate locked for year one, and a vote on which recurring VUS the first functional-assay batch resolves
refund · Fully refundable any time before the pilot start date, and within the first 30 days if the lab's geneticists find the drafts unusable.
target · 3 paid $1,000 deposits from 10 pitched labs within 30 days
before taking money · Every draft interpretation must be labeled research use only and signed out by the lab's own board-certified geneticist; do not deliver interpretations to clinicians or patients before CLIA counsel review.
Go: build it if
5 signed reciprocity LOIs from 12 calls, drafts rated sign-out-ready by 4 of 6 labs, and 3 paid $1,000 deposits - labs will contribute and pay; build the workbench before any assay capex.
Kill: stop if
2 or fewer LOIs from 12 calls, or 0 of 10 labs pay after seeing their own scored 48-hour drafts - classifications are treated as proprietary exactly as the stated risk says; stop.
5 Scripts to run itoutreach message, landing copy, deposit terms · click to open
outreach message
You already submit classifications to ClinVar, but the case-level evidence behind them dies in your LIMS, and your geneticists still spend 2-plus hours on every hard VUS. I'm building Allelium, a shared evidence network for mid-size labs: contribute anonymized classifications and evidence, see what every member lab concluded, and vote on which recurring VUS our functional-assay pipeline resolves first. Send me 10 of your hardest VUS and I'll return draft dossiers within 48 hours. Do you have 20 minutes this week?
landing page
Draft variant interpretations backed by every member lab's evidence $500 per geneticist seat per month plus $10 per signed-out report; the 3-month founding pilot is $3,000, reserved for $1,000 Reserve a founding-lab seat - $1,000, refundable until your pilot starts
deposit terms
The $1,000 deposit reserves one of 10 founding-lab pilot slots and is credited to your $3,000 three-month pilot. It is fully refundable any time before your pilot start date, and within the first 30 days if your geneticists find the drafts unusable. Founding labs lock $500 per seat per month for year one and vote on the first functional-assay batch.
Would you run this test?
One tap. The yes-share feeds the Demand pillar of this idea's score; nobody sees who answered.
Budgets are out-of-pocket estimates for a team of one to three, US market. Size the deposit to the deal, and check the terms before taking money in a regulated line.
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
96
Idea Score, 0-100 · raw 59.5 x 1.61
Warm
competition: more crowded than 32% of ideas · headwind x0.84
+4.4
government priorities, secondary (80 matching grants)
Trend
51
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)13
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
77
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain100
100x potential
72
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis67
- Moat axis100
- Neighbours still alive67
- Technologist judge100
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were shared, evidence, network, genetic, test, report, subscription, workbench.
The idea in full
- What
- A subscription workbench for hospital and reference sequencing labs that drafts variant interpretations for cancer and rare disease reports. Every subscribing lab contributes anonymized classifications and case-level evidence back to a shared knowledge graph, and Allelium runs its own automated functional-assay facility that resolves the variants of uncertain significance the network flags most often, feeding results back to all members. Labs sign up online and pay per seat and per signed-out report; no sales team required for mid-size labs.
- Why now
- The 2024 cohort added 199 new healthcare and bio companies, roughly double 2023's 98, with sequencing-driven bets like Gamgee (scalable personalised cancer treatment) and TareBio (vaccines for any cancer in weeks) pushing test volume up while interpretation capacity stays flat; the bottleneck has moved from reading DNA to signing out reports.
- Wedge: first customer and entry point
- Mid-size oncology labs whose geneticists spend hours per case on variants of uncertain significance; start with a free lookup layer that shows what other labs concluded, convert to paid workbench.
- Path to 100x
- Genomic testing is a market in the tens of billions and every report needs an interpretation, so the winner becomes the reference layer the whole industry cites. Each new lab makes every other lab's reports more accurate, a compounding data network effect where the second-place network is strictly worse and clinical users cannot afford strictly worse.
- Ceiling
- The largest reference labs keep interpretation in-house and never join, capping the network at mid-tier labs and a few hundred million in revenue.
- Closest real companies, as the generator saw them
- Slideflow Labs builds AI biomarkers from pathology slides, single-modality and single-vendor; Gamgee personalizes cancer treatment downstream of the report; Lattice Health governs deployed imaging AI rather than generating interpretations. None operates a cross-lab evidence network with wet-lab resolution of disputed variants.
- Main risk
- Labs treat their variant classifications as proprietary and refuse to contribute, leaving the network cold-started on public data alone.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
Genuine data network effect, but the largest reference labs staying in-house caps this at a few hundred million by its own admission.
Bootstrapper
3/5
Self-serve per-report pricing to labs already paying geneticist hours is strong, but the in-house functional-assay facility is real capex.
Operator
5/5
Lab geneticists burn hours per case on variants of uncertain significance and labs bill per signed-out report, so the pain and budget sit in the same hands.
Technologist
5/5
Running an own functional-assay facility to resolve the variants the shared graph flags means the knowledge base literally compounds with lab usage.
Risk
5/5
Self-serve across many mid-size labs, own functional-assay facility, no gatekeeping channel, and the subscribing labs carry the clinical regulatory burden.
trends
2/5
Sequencing volume has outrun interpretation for a decade; a 199-company 2024 cohort shows crowding, not a 2025-2026 shift making this sellable now.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (shared, evidence, network, genetic, test, report, subscription, workbench): 15 all-time, 2 from the last two years. Same matching as Idea Check.
Redcliffe Labs is India's Largest Omni-channel Diagnostics platform
Head Diagnostics offers AI-driven digital tools for cognitive and neurological assessment.
AI that eliminates manual workflows, enabling businesses to serve more customers faster.
Personalized prevention using genetics and AI
Developer of a healthcare platform designed to ensure better outcomes through the use of diagnostic tests and lab reports. The company's product digitizes collected data from disparate hardware providers, interprets it, and then creates analytics dashboards to see how both individual patients and groups of patients are doing, enabling healthcare providers to determine treatment plans and pharmaceutical options for patients.
AI-powered scalable infrastructure + mental health services, starting…
We treat women with Polycystic Ovary Syndrome in India
AI variant interpretation for genetic diagnostics.
Vanta—the proven leader in automated compliance helping startups…
The financial foundation for every real estate development decision
One clinic for every sleep issue
Rare Disease-Focused Care Delivery and Evidence Generation Platform
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1327
startup-relevant grants in Healthcare and bio
$703M
awarded in the sector, tracked
127
opportunities open now in the sector
- CARDIAC CASCADE: Cardiomyopathy and Arrhythmia Risk Dissemination through Innovative Family Sharingawardhigh relevance
NIH / NHGRI · STTR phase I · $301K · posted 2025-09-22
NIH / NIMH · STTR phase II · $450K · posted 2025-09-12
NIH / NINDS · SBIR phase II · $497K · posted 2025-09-01
- Integrating nowcasting models with digital communications to reduce the asthma burden in rural areasawardhigh relevance
NIH / NHLBI · SBIR phase II · $313K · posted 2026-09-01
NIH / NHLBI · SBIR phase I · $309K · posted 2026-09-01
- Machine Learning-Driven Precision Dosing System for Improved Anticoagulation Therapyawardhigh relevance
NIH / NHLBI · SBIR phase I · $374K · posted 2026-09-01
- Project VELA: A Cloud-Based, Model-Agnostic Federated Query Tool to Enable Scalable, Inclusive Multi-Site Research Across Health Systemsawardhigh relevance
NIH / NIMHD · SBIR phase I · $307K · posted 2026-08-28
- Small Molecule Notch Agonist as a Therapeutic for Liver Disease in Alagille Syndromeawardhigh relevance
NIH / NIDDK · SBIR phase I · $305K · posted 2026-08-20
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 135 → 121 → 224 → 171 → 103 new companies 2022 → 2026 · 92% aliveYC F26 live: 1 in this cluster, 2% of the batch (was 6% in S26)Since February, of 444 YC companies here: 5 acquired, 5 shut down, 41 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Enterprise
- Business model
- Software subscription
- Path to 100x
- Network effects, winner takes most
- Market size
- $10-100B market
- Capital intensity
- Capital-heavy (hardware, bio, infra)
- Speed to revenue
- Revenue in 1-3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Network effects
- Geography
- Global from day one
- Regulation
- Some regulation
- Vibe
- Boring business
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.